EXPAREL achieves statistically significant reductions in opioid consumption and pain score
Pacira Pharmaceuticals announced its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours. January 16, 2019